March 2005, Volume 27, No. 3
Original Article

The prescription pattern of first-line antihypertensives among family medicine trainees in Hong Kong - Part 2: in the presence of diabetes

Martin C S Wong 黃至生, Roger Y Chung 鍾一諾

HK Pract 2005;27:83-93

Summary

Objective: There has been much debate on prescribing first-line antihypertensive agents for patients with diabetes mellitus in the primary care setting. This survey studies the prescription pattern among family medicine trainees in hypertensives with uncomplicated diabetes.

Design: Cross-sectional telephone interviews conducted from December 2003 to January 2004.

Subjects: All basic and higher trainees of the Hong Kong College of Family Physicians as of December 2003

Main outcome measures: (1) the prescription proportion of antihypertensive agents in different ages and genders (2) the effect of training status on the prescription of angiotensin-converting enzyme inhibitors (ACEIs) (3) The relationship between ACEI prescription and experience of practice; and (4) whether physician gender would affect patterns of prescription.

Results: We conducted 101 complete telephone interviews. ACEIs were the most popular (52-67%) in all ages and gender groups, and diuretics were more commonly prescribed in the elderly. There had been no difference in prescription proportion of ACEIs between basic and higher trainees. Trainees who prescribed ACEIs among the elderly age groups had lesser number of years after graduation as compared to those choosing other agents (0.02 < p < 0.05). Gender-based differences did not exist in the prescription of various classes of antihypertensives.

Conclusion: This survey revealed the common usage of ACEIs in diabetic hypertensives. As there were few Asian studies on the adverse effect profiles of ACEIs, we suggested a large scale prospective study on the tolerability profile of various antihypertensives in diabetes patients to justify the best first-line agent.

Keywords: First-line, antihypertensives, prescription, diabetes

摘要

目的: 在糖尿病患者應處方何種第一線抗高血壓藥的問題上,醫學界一直存有爭議。本調查研究家庭醫學訓練生對無併發症糖尿病患者使用抗高血壓藥的模式。

設計: 由二零零三年十二月至二零零四年一月進行電話訪問。

研究對象: 二零零三年十二月香港家庭醫學院所有基礎及高級程度訓練生。

主要測量內容: (1)訓練生在不同年齡及性別糖尿病人處方抗高血壓藥的模式; (2)受訪者的訓練階段對處方血管緊張素轉化阻礙劑(ACEIs)的影響; (3)轉化阻礙劑之處方與臨床經驗的關係;(4)醫生性別對處方模式的影響。

結果: 我們進行了101個完整的電話訪問。轉化阻礙劑在各年齡和性別病者之使用均很普遍, 佔52-67%,而利尿劑亦較多在老年病患者中處方。基礎及高級程度訓練生在ACEIs的處方比率上沒有統計學上之差異。 在老年病患者中,選擇轉化阻礙劑之訓練生比選擇他類抗高血壓藥者畢業後年期較短(0.02 < p < 0.05)。醫生性別對處方模式沒有明顯影響。

結論: 轉化阻礙劑在糖尿病患者中為常用降血壓藥物,但是缺乏有關副作用對亞洲人影響之學術研究。我們建議進行大型糖尿病人抗高血壓藥物耐受性之前瞻性研究,使醫生選擇第一線抗高血壓藥物時有更多參考。

主要詞彙: 第一線,抗高血壓藥物,處方,糖尿病。


Introduction

Angiotensin-converting enzyme inhibitors (ACEIs) has been recommended by many authorities as a first-line pharmacological option in managing patients with diabetes mellitus and hypertension.1,2 Indeed, some suggested that diuretics and b-blockers should be used only with caution as the former may aggravate diabetes and the latter may worsen glucose tolerance and mask hypoglycaemia.3 Similar to angiotensin receptor blockers (ARBs, like irbesartan and losartan), the reno-protective effect of ACEIs on halting the progression of diabetic nephropathy and reduction of albuminuria is well pronounced.4,5 As substantiated by Wright,6 meta-analyses show that ACEIs are effective in preserving renal function in both diabetic7 and non-diabetic8 proteinuric nephropathy (defined as more than 3 g/d).

Indeed, ARBs have been explicitly highlighted by the seventh report of the Joint National Committee9 to be effective in reducing progression to macroalbuminuria,5, 10 although other classes of antihypertensive agents are also acceptable with firm clinical trial basis.9 These include National Kidney Foundation _ American Diabetes Association (NKF-ADA) guidelines,11,12 United Kingdom Prospective Diabetes Study (UKPDS),13 and Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT).14 Alarmingly, the prevalence of micro- and macro-albuminuria among Asian hypertensive type 2 diabetics have been estimated as 39.8% (39.2-40.5; 95% CI) and 18.8% (18.2-19.3; 95% CI) respectively. Since these figures may imply an "impending pandemic of diabetic cardiovascular and renal diseases in Asia with its potential economic consequences",15 ACEIs and ARBs seem to be attractive first-line options.

Of interest is the finding from the same study that intakes of diuretics and calcium channel blockers (CCBs) were among the highlighted predictive factors for the presence of macroalbuminuria,15 hence raising concerns about possible harms of diuretics and CCBs to a known diabetic.

However, recent debate arose as to the best first-line antihypertensive in diabetic patients. For instance, in the Patient-Oriented Evidence that Matters (POEM) session16 of the British Medical Journal, diuretics was labelled as the least expensive and most effective agent, and "... should be the first line treatment almost everyone with hypertension, including patients with diabetes...". It was argued that none of the other first line drugs were significantly better than low dose diuretics for any outcomes, but that most cost considerably more than diuretics.

In fact, a study of the usage patterns of antidiabetic and antihypertensive drugs in Hong Kong17 found that most patients with diabetes in the General Out-Patient Clinics (GOPCs) were prescribed indapamide (72.7%) as the only antihypertensive agent, and in the specialist clinics (SCs) ACEIs (35%) and indapamide (22.5%) were the most popular.

Whereas in standard textbooks of family medicine1 diuretics has been regarded as "contraindications" in prescribing for maturity-onset diabetic patients, recent controversies and study findings may influence patterns of antihypertensive prescription in GOPCs, SCs and integrated clinics.

In response to these inconsistencies in recommendations, the present study investigates how family medicine trainees choose first-line antihypertensives agents in known diabetic patients.

Methods

We conducted 101 telephone interviews from December 2003 to January 2004.

The survey enquired on the preferred first-line agent prescribed by the participants in the newly diagnosed hypertensives of different ages and genders with co-existing diabetes (i.e. questions 3 and 4; see appendix which was extracted from the full questionnaire18). The questions assumed the diabetic patient had no complications on presentation, including various forms of nephropathy. Eligible participants included the basic and higher family medicine trainees registered in the Hong Kong College of Family Physicians (HKCFP) in the year 2002-2003.

"Basic trainees" are those undergoing hospital- or community-based training offered by HKCFP in the study period. trainees in the college; or had just completed the higher training in 2002 certified and acknowledged by the Board of Vocational Training and Standards (BVTS) in the college's Annual Report 2002-2003.19

One of the authors contacted each cluster representative (or an equivalent coordinator) for basic trainees, and study group leaders for higher trainees. They were requested to invite trainees' participation. The telephone numbers of trainees could only be obtained when explicit and informed verbal consent of each trainee was available.

After obtaining participants' consent, we further assured interviewees' anonymity, confidentiality and the sole purpose of collecting data for research.

We compared the prescription proportion of ACEIs between basic trainees (including hospital and community-based) and higher trainees using c2 tests. We also compared practice experience among those choosing ACEIs versus those not choosing ACEIs by the student's t-tests, with an assumption of normality. In addition, the correlation between physician gender and ACEI prescription was also studied by Fisher's Exact tests. An a value of 0.05 was adopted in all tests, and all comparisons of continuous variables were two-sided.

We defined "higher trainees" as doctors who had completed four years of basic training; current higher.

Results

We received 142 telephone numbers, and 101 complete telephone surveys were conducted by a single investigator (Table 1). The other 41 potential participants could not be contacted in the study period. There was no refusal or withdrawal during the survey after thorough explanation of the nature of the interview, as well as the ethical issues concerned.

For the basic trainees, the majority of participants chose ACEIs (67%) as first-line agents regardless of age and gender (Table 2). This was followed by CCBs (16%) in the young patients, whereas diuretics (16%) were more popular in the elderly patients. Overall, patient gender had no effect on physicians' choice of first-line drugs.

Similarly, ACEIs (52% to 64%) were the most commonly prescribed among the higher trainees. Diuretics (32%) also enjoyed higher popularity in the elderly population as compared with the young (16%), in both male and female patients. On the contrary, very few higher trainees chose CCBs.

One higher trainee, who was indifferent to the class of antihypertensives in prescribing for patients without concomitant risk factors, selected ACEIs in the presence of diabetes in all ages and genders. In addition, another higher trainee who chose candesartan cilexetil (Blopress, an Angiotensin A2-receptor blocker) and bisoprolol fumarate and hydrochlorothiazide (Lodoz, a b-blocker and diuretic combination) for the young and elderly age groups in the absence of diabetes, kept his choice of blopress for the young age group but changed to Losartan and hydrochlorothiazide (Hyzaar, an ARB and diuretic combination) for the elderly if diabetes was present, for both male and females.

The proportion of prescribing ACEIs (52% to 67%) remained high for both basic and higher trainees (Table 3). There was however less higher trainees (52%) choosing ACEIs for the elderly males and females, although the present finding cannot reveal statistical significance.

Analyzing all participants as a whole (Table 4), those who prescribed ACEIs among all patient age and gender groups were found to have lesser number of years after graduation (around 3.7 versus 4.4 years for those choosing other agents). In particular, among the elderly patients, the difference in the number of years was significant (0.02 < p < 0.05) between the "ACEI-prescribers" and "non-ACEI prescribers". In other words, the more experienced trainees tend to choose agents other than ACEIs for the elderly age groups.

As regards the effect of physician genders on prescription pattern (Table 5), more female doctors seemed to prescribe b-blockers than male doctors for both young patients (16.2% vs. 7.8%) and elderly patients (13.5% vs. 3.1%), despite the absence of statistical significance. The other antihypertensive classes did not reveal correlation between physician gender and prescription proportion.

Discussion

The co-existence of diabetes and hypertension is significant, and they have been implicated as multiplicative risk factors for cardiovascular diseases.20

A thorough discussion of antihypertensive agents in new-onset diabetes,21 including trial evidence of Renin-Angiotensin System (RAS) blockade by ACEIs and ARBs, has been reviewed in the December, 2004 issue of The Hong Kong Practitioner. Chan et al21 highlighted the limitations of existing hypertension guidelines, and that "drugs blocking the renin-angiotensin system could be considered as initial choice of antihypertensive therapy in overweight hypertensive patients" as one of their key messages.

One might intuitively extend the insightful commentary by Chan et al21 to the prescription of first-line antihypertensives patient already diagnosed having diabetes; namely ACEIs or ARBs, could be pretty high in the list of physicians' drug choice. This is especially true as there is still controversy on the best first-line agent. No trainees have chosen ARBs in the present study as first line agents, which may be due to drug availability in their clinics, administrative or cost concerns.

However the choice of first-line agent is still a challenging one as we review more emerging evidence. For instance, the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial22 reminded us of the higher six-month cardiovascular mortality in valsartan-based therapy versus amlodipine-based ones, which could be attributed to poorer blood pressure control of the former. As argued by Cheung23 based on VALUE, meticulous control of blood pressure should be the prime concern, and that the debate on which class of antihypertensive may only be of financial interest.

The popularity of ACEIs among basic and higher trainees (Table 2 and 3) could be explained by the factors above-mentioned, authoritative textbook teachings,1,3 and concerns over other agents to wreak havoc (like interstitial nephritis if diuretics were chosen24). The reasons why diuretics were more commonly chosen in the elderly (Table 2) could again be textbook recommendations;1 whereas the potential sexual dysfunction and electrolyte disturbances accompanying diuretics were rather intolerable in the young, working, sexually active populations who also need regular monitoring of their glycemic status.

The finding that those not choosing ACEIs in the elderly patients were among the more experienced trainees (Table 4) is of interest. This group of physicians could be more exposed to recent evidence- based (and sometimes expert-opinion based) arguments suggesting more evidence of beneficial effects on morbidity and mortality with older antihypertensive drugs, like systematic reviews from MEDLINE and the Cochrane Library25 and the series of 3 articles by Wright.6, 26, 27

Indeed, a recent study by Tam et al28 in the October issue of the Hong Kong Medical Journal, 2004, has shed light into the prescription of ACEIs in different ages and genders. They found a positive association of advanced age (p = 0.002) and female sex (p < 0.001) with microalbuminuria in diabetes in 3 local clinics. Their contributions might indicate a lower threshold for physicians prescribing ACEIs in elderly and/or female diabetes, although we should bear in mind that older people responded less well to AECI suppression, "because their renin-angiotensin systems are more suppressed".29 This speculative assumption should however be explored further by larger scale studies.

In other countries, gender-based differences in the prescription of antihypertensive agents were demonstrated, and were affected by physicians' training level and patient comorbidities. For instance, one study found that male doctors preferred b-blockers while female doctors prescribed methyldopa more extensively in diabetic hypertension.30 Our present study (Table 5) did not reveal the effect of gender on antihypertensive choice in our locality.

We wish to infuse one more important factor to consider in the choice of a first-line agent in the presence of diabetes, namely drug tolerability. Among evidence-based guidelines in recommendations of best first-line agents, this has received relatively little attention as many concerns have been on the cardiovascular end-points. Disregarding the potency of ACEIs or ARBs in halting nephropathy, if diabetic patients are simply not taking the first-line antihypertensives due to their side-effects, or even experience serious adverse reactions causing default to follow up, this would hinder our commitment as primary care physicians in excelling chronic disease management. For instance, would you prescribe captopril to a diabetic if the odds of inducing intolerable cough is as high as, say, 40%?

So far we could barely observe any local data on drug tolerability. Hence we hereby suggest a prospective research studying the tolerability pattern of various antihypertensive agents in the primary care setting, the result of which would then allow a more informative choice of first-line drugs in our locality.

Acknowledgements

The authors would like to thank all participants who have contributed their invaluable time and opinions.

Key messages

  1. Angiotensin-converting enzyme inhibitors (ACEIs) were the most common first-line antihypertensive agents prescribed by trainees in diabetic patients.
  2. Diuretics were more popular among elderly populations.
  3. Training status and gender of physicians had no impact on the prescription proportion of ACEIs.
  4. Among the elderly patients, the more experienced trainees tend to choose agents other than ACEIs.


Martin C S Wong, BMedSc (Hons), MSc (Hons), MBChB (CUHK), MPH (CUHK)
Honorary Clinical Tutor,
Department of Community and Family Medicine, Chinese University of Hong Kong.

Roger Y Chung,
Graduate Student,
Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, USA.

Correspondence to : Dr Martin C S Wong, 4/F, Lek Yuen Health Centre, 9 Lek Yuen Street, Shatin, NT, Hong Kong.


References
  1. Murtagh J. General Practice, second edition. McGraw-Hill Book Company Australia Pty Limited. 1999;Table 111.6:1082.
  2. Michigan Quality Improvement Consortium. Medical management of adults with essential hypertension. Southfield (MI): Michigan Quality Improvement Consortium; 2003 Aug. 1 p.
  3. Kumar P, Clark M. Clinical Medicine: A Textbook for Medical Students and Doctors. Third edition 1994;Table 11.38:622.
  4. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-1462.
  5. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiocadcular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
  6. Wright JM. Choosing a first-line drug in the management of elevated blood pressure: What is the evidence? 3: Angiotensin-converting- enzyme- inhibitors. CMAJ 2000;163:293-296.
  7. Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993;118:129-138.
  8. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of non-diabetic renal disease: a meta-analysis of randomised trials. Ann Intern Med 1997;127:337-345.
  9. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. US Department of Health and Human Services, NIH Publication No. 03-5233, May, 2003:15.
  10. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
  11. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003;26 (suppl 1): S80-S82.
  12. National Kidney Foundation Guideline. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002;39 (suppl 2):S1-S246.
  13. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-720.
  14. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
  15. Wu AY, Kong NC, de Leon FA, et al. for the MAPS Investigators. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 2004 Dec 23; [Epub ahead of print].
  16. Filler. Diuretics should be the first line treatment for hypertension. BMJ 2003; 327 (30 August).
  17. Lau GS, Chan JC, Chu PL, et al. Use of antidiabetic and antihypertensive drugs in hospital and outpatient settings in Hong Kong. Ann Pharmacother 1996;30:232-237.
  18. Wong MCS, Chung RY. The prescription pattern of antihypertensives among Family medicine trainees in Hong Kong Part 1: in the absence of concomitant cardiovascular risk factors. HK Pract 2004;26:420-429 see appendix for full questionnaire.
  19. Annual Report 2002-2003, pp.18-23. The Hong Kong College of Family Physicians. Submitted by the Honorary Secretary at the HKCFP Annual General Meeting on 12th December, 2003 (Under Board of Vocational Training and Standards, p. 17-18, "Higher trainees" include those from (a). "Output Congratulations", (b). Certified completion of 4-year Basic Training; (c). Certified completion of 2-year Higher training, and (d). Appendix A: Trainees in Higher Vocational Training in Family Medicine 2002/2003)
  20. World Health Organization / International Society of Hypertension Guidelines. J Hypertens 1999;17:151-183.
  21. Chan NN, Kong APS,Chan JCN. New-onset diabetes and antihypertensive drugs: implications for renin-angiotensin system blockade. HK Pract 2004;26:515-519.
  22. Julius S, Kjeldsen SE, Weber M. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004;362:2022-2031.
  23. Cheung BMY. Sartans for hypertension - implications of the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial. HKMJ 2004; 10: 359.
  24. Posch PJ. Diuretics and diabetes. (Rapid responses to "Diuretics should be the first line treatment for hypertension. BMJ 2003; 327 (30 August)) BMJ 2003;4 Sept.
  25. Wright JM, Lee C, Chambers GK. Systematic review of antihypertensive therapies: Does the evidence assist in choosing a first-line agent? CMAJ 1999;161:25-32.
  26. Wright JM. Choosing a first-line drug in the management of elevated blood pressure. What is the evidence? 1: Thiazide diuretics. CMAJ 2000; 163: 57-60.
  27. Wright JM. Choosing a first-line drug in the management of elevated blood pressure. What is the evidence? 2: b-blockers. CMAJ 2000;163:188-192.
  28. Tam TKW, Cheng LPK, Lau DMW, et al. The prevalence of microalbuminuria among patients with type II diabetes mellitus in a primary care setting: cross-sectional study. HKMJ 2004;10:5.
  29. Williams B. Drug treatment of hypertension (Editorials) BMJ 2003;326:61-62.
  30. Sequeira RP, Jassim AK, Damanhori, et al. Physician gender and antihypertensive prescription pattern in primary care. J Eval Clin Pract 2003;9:409-415.

Appendix

Appendix: Abridged version of Sample Questionnaire
(Reproduced from reference 18 with permission; only Questions 3-4 were analyzed in this article)
 
 
Sex (性別):______
 
Years after graduation (畢業後年期):_________
 
Training status:
(醫學訓練階段)
  Higher trainees (高級程度訓練)
  Basic trainees, Community-based (社區為本基礎訓練)
  Basic trainees, Hospital-based (醫院為本基礎訓練)
       
Location of practice (執業地點):________________________
 

(1)* In your own present practice, which drug would you mostly use as your first-line anti-hypertensive in a young (< 65 y.o.) and an elderly (> 65 y.o.) male patient newly diagnosed as having hypertension (HT)? He enjoyed good past health and had no concomitant cardiovascular risk factors.
在你現時執業的地方,當處理一位剛被診斷為高血壓的 (A) 年輕 (少於65歲)及 (B) 年長 (超過65歲)的男性病人時,你最先會選擇什麼抗血壓藥物?他以往的健康良好,亦沒有其他循環系統的高危因素。

 

(A) Young HT ____________________________ (Drug name)
(B) Elderly HT____________________________ (Drug name)

 
(2) If the above patient was female, what would be your drug of choice?
若以上病患者為女性,你處方的藥物為何?
 
(A) Young HT ____________________________ (Drug name)
(B) Elderly HT____________________________ (Drug name)
 
(3) If the male patient was now having diabetes mellitus, what would be your drug of choice?
若以上的男性高血壓患者同時患上糖尿病,你處方的藥物為何?
 
(A) Young HT ____________________________ (Drug name)
(B) Elderly HT____________________________ (Drug name)
 
(4) If the female patient was now having diabetes mellitus, what would be your drug of choice?
若以上的女性高血壓患者同時患上糖尿病,你處方的藥物為何?
 
(A) Young HT ____________________________ (Drug name)
(B) Elderly HT____________________________ (Drug name)
 
 
*Notes:

If clarification from the respondents was met, the interviewer would highlight the following points:
(1) There would be no compelling indications nor contraindications for whatever drugs subsequently chosen;

(2) On subsequent physical examinations, no complications were found

(3) The patient did not show any preference towards a particular medication

 
~ ~ ~ Thank you very much ~ ~ ~